Irbesartan/Hydrochlorothiazide LPN 150/12.5 irbesartan 150 mg and hydrochlorothiazide 12.5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

irbesartan/hydrochlorothiazide lpn 150/12.5 irbesartan 150 mg and hydrochlorothiazide 12.5 mg tablet blister pack

lupin australia pty limited - hydrochlorothiazide,irbesartan -

Irbesartan/Hydrochlorothiazide Lupin 300/12.5 irbesartan 300 mg and hydrochlorothiazide 12.5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

irbesartan/hydrochlorothiazide lupin 300/12.5 irbesartan 300 mg and hydrochlorothiazide 12.5 mg tablet blister pack

lupin australia pty limited - hydrochlorothiazide,irbesartan -

Irbesartan/Hydrochlorothiazide SAN 150/12.5 irbesartan 150 mg and hydrochlorothiazide 12.5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

irbesartan/hydrochlorothiazide san 150/12.5 irbesartan 150 mg and hydrochlorothiazide 12.5 mg tablet blister pack

lupin australia pty limited - hydrochlorothiazide,irbesartan -

Irbesartan/Hydrochlorothiazide LUP 150/12.5 irbesartan 150 mg and hydrochlorothiazide 12.5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

irbesartan/hydrochlorothiazide lup 150/12.5 irbesartan 150 mg and hydrochlorothiazide 12.5 mg tablet blister pack

lupin australia pty limited - hydrochlorothiazide,irbesartan -

BLOOMS THE CHEMIST IRBESARTAN HCTZ 300/25 irbesartan and hydrochlorothiazide 300/25mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

blooms the chemist irbesartan hctz 300/25 irbesartan and hydrochlorothiazide 300/25mg tablet blister pack

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; croscarmellose sodium; magnesium stearate; iron oxide yellow; iron oxide red; titanium dioxide; hypromellose; macrogol 4000; iron oxide black - for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

TERRY WHITE CHEMISTS IRBESARTAN HCTZ 300/25 irbesartan and hydrochlorothiazide 300/25mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

terry white chemists irbesartan hctz 300/25 irbesartan and hydrochlorothiazide 300/25mg tablet blister pack

apotex pty ltd - hydrochlorothiazide,irbesartan -

CHEMMART IRBESARTAN HCTZ 300/25 irbesartan and hydrochlorothiazide 300/25mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

chemmart irbesartan hctz 300/25 irbesartan and hydrochlorothiazide 300/25mg tablet blister pack

apotex pty ltd - hydrochlorothiazide,irbesartan -

IRBESARTAN HCT MEDIS 300/25 irbesartan/hydrochlorothiazide 300 mg/ 25 mg tablet blister Australia - English - Department of Health (Therapeutic Goods Administration)

irbesartan hct medis 300/25 irbesartan/hydrochlorothiazide 300 mg/ 25 mg tablet blister

medis pharma pty ltd - hydrochlorothiazide, quantity: 25 mg; irbesartan, quantity: 300 mg - tablet - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; hydrogenated castor oil; colloidal anhydrous silica; maize starch - irbesartan hct medis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

IRBESARTAN AND HYDROCHLOROTHIAZIDE- irbesartan and hydrochlorothiazide tablet, film coated United States - English - NLM (National Library of Medicine)

irbesartan and hydrochlorothiazide- irbesartan and hydrochlorothiazide tablet, film coated

nucare pharmaceuticals, inc. - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - irbesartan 300 mg - irbesartan and hydrochlorothiazide tablets usp are indicated for the treatment of hypertension. irbesartan and hydrochlorothiazide tablets usp may be used in patients whose blood pressure is not adequately controlled on monotherapy. irbesartan and hydrochlorothiazide tablets usp may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. the choice of irbesartan and hydrochlorothiazide tablets usp as initial therapy for hypertension should be based on an assessment of potential benefits and risks. patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. the decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental like

IRBESARTAN AND HYDROCHLOROTHIAZIDE tablet IRBESARTAN AND HYDROCHLOROTHIAZIDE tablet, film coated United States - English - NLM (National Library of Medicine)

irbesartan and hydrochlorothiazide tablet irbesartan and hydrochlorothiazide tablet, film coated

alembic pharmaceuticals inc. - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - irbesartan 150 mg - irbesartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension. irbesartan and hydrochlorothiazide tablets may be used in patients whose blood pressure is not adequately controlled on monotherapy. irbesartan and hydrochlorothiazide tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. the choice of irbesartan and hydrochlorothiazide tablets as initial therapy for hypertension should be based on an assessment of potential benefits and risks. patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. the decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal w